| Literature DB >> 19995389 |
Antonio Maria Risitano1, Carmine Selleri, Bianca Serio, Giovanni Fernando Torelli, Alexander Kulagin, Sébastien Maury, Jörg Halter, Vikas Gupta, Andrea Bacigalupo, Gerard Sociè, André Tichelli, Hubert Schrezenmeier, Judith Marsh, Jakob Passweg, Bruno Rotoli.
Abstract
An alemtuzumab-based experimental immunosuppressive treatment (IST) regimen was investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure white cell aplasia (PWCA). Alemtuzumab total dose was 73-103 mg s.c., followed by cyclosporine. No serious toxicity due to the regimen was observed. Adverse events were clinically irrelevant; infectious events were rare. The total response rate was 58%, 84% and 100% in SAA, PRCA and PWCA, respectively, with corresponding 6 months cumulative response probabilities of 84%, 84% and 100%. Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune-mediated marrow failures.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19995389 DOI： 10.1111/j.1365-2141.2009.08027.x
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998